Loading in 2 Seconds...
Loading in 2 Seconds...
Pat F. Bass III, MD CMIO LSU-Health Shreveport ICON Steering Committe. Benefits of LSU ICON for LSUHSC Shreveport. Access to data analysis/statistical support Dedicated Patient Interaction Specialist to assist in recruiting and data collection Centralized research support/ mentoring.
Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.
CMIO LSU-Health Shreveport
ICON Steering Committe
This project is designed to compare the operative and non-operative outcomes of some of the most common spinal problems. Such diagnoses as Back Pain, Lumbar Disk Disease and Spinal Stenosis are prevalent in this country and are some of the most frequent sources of disability and pain complaints. Treatment of these problems consume an increasingly large fraction of the present healthcare costs. Various surgical procedures are utilized in the management of such conditions but the relative value of these procedures have not, in most instances, been established. This project attempts to prospectively compare the outcomes of patients, as measured from their perspective and their functional capability, when treated by surgical versus non surgical management.
Retrospective Observational Study of Physician Response and Cost Effectiveness of Rapid Identification of Staphyloccus Species and Methicillin Susceptibility Results Using Verigene BC-S Assay in Aerobic Bottles from Adult Hospitalized Bacteremic Patients
This projects will determine the effect of a rapid test for identification of bloodstream pathogens on physician response and healthcare costs. Using classical biochemical methods, bacteria are identified within 48 hours; however, we have verified a new test that uses a molecular signal-amplification method to identify methicillin-resistant Staphylococcus aureus (MRSA), methicillin-susceptible Staph. aureus (MSSA), and coagulase-negative staphylococci (CoNS) in 4 hours. MSSA identification allows for a switch from empiric vancomycin therapy to nafcillin, a more effective drug for MSSA, which may cause the patient to get better faster and decrease the length of hospital stay. We will assess clinician response to faster results and determine if there is an impact on healthcare costs. Comparing control patients (with bacteria identified classically) to experimental patients (with bacteria identified molecularly), calculation of healthcare costs may reveal a difference. We expect that faster MSSA results lead to modification of empiric therapy, shorter stay, and decreased costs.